Brokerage firm Barclays Upgrades its rating on Hologic(NASDAQ:HOLX). In a research note issued to the investors, the brokerage major Raises the price-target to $44.00 per share. The shares have been rated Overweight. Previously, the analysts had a Equal-weight rating on the shares. The rating by Barclays was issued on Sep 23, 2016.
In a different note, On Jul 28, 2016, Jefferies said it Maintains its rating on Hologic. In the research note, the firm Raises the price-target to $42.00 per share. The shares have been rated ‘Buy’ by the firm. On Jul 28, 2016, Morgan Stanley said it Maintains its rating on Hologic. In the research note, the firm Raises the price-target to $38.00 per share. The shares have been rated ‘Equal-weight’ by the firm. On Jul 28, 2016, Evercore ISI Group said it Upgrades its rating on Hologic. The shares have been rated ‘Buy’ by the firm.
Hologic (HOLX) made into the market gainers list on Tuesdays trading session with the shares advancing 2.08% or 0.79 points. Due to strong positive momentum, the stock ended at $38.76, which is also near the day’s high of $39.075. The stock began the session at $37.88 and the volume stood at 32,19,505 shares. The 52-week high of the shares is $41.66 and the 52 week low is $31.84. The company has a current market capitalization of $10,753 M and it has 27,74,22,860 shares in outstanding.
Hologic(HOLX) last announced its earnings results on Jul 27, 2016 for Fiscal Year 2016 and Q3.Company reported revenue of $717.40M. Analysts had an estimated revenue of $704.27M. Earnings per share were $0.51. Analysts had estimated an EPS of $0.48.
Several Insider Transactions has been reported to the SEC. On Jul 25, 2016, Sally Crawford (director) sold 16,071 shares at $37.00 per share price.Also, On Jul 25, 2016, Nancy Leaming (director) sold 8,179 shares at $37.00 per share price.On Jun 2, 2016, Lawrence M Levy (director) sold 17,794 shares at $34.41 per share price, according to the Form-4 filing with the securities and exchange commission.
Hologic Inc. is a developer manufacturer and supplier of diagnostics products medical imaging systems and surgical products. The Companys business units are focused on diagnostics breast health GYN surgical and skeletal health. The Companys diagnostics products include Aptima family of assays its ThinPrep system the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases chlamydia and gonorrhea certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis the parasite that causes trichomoniasis. The Companys GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems an ultrasound-based osteoporosis assessment product and its Fluoroscan mini C-arm imaging products.